Business Description
BLS Pharmaceuticals Ltd
ISIN : AU0000477796
Total Employee Number:
16Compare
Compare
Traded in other countries / regions
BLS.AustraliaPR8.Germany IPO Date
2000-12-14Description
BLS Pharmaceuticals Ltd is an Australian life sciences and health products business. The Group provides pharmaceutical manufacturing, wholesale, and distribution services, and own-brand (Dr Watson) prescription medicines and health products in Australia, Europe, Japan, the United States, and the United Kingdom. Its focus is on the development and commercialisation of medical cannabis, psychedelics, and novel foods and consumer health products under its own brands and manufacturing for third-party brands. The group's clients include licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.42 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.27 | |||||
Debt-to-EBITDA | 0.61 | |||||
Interest Coverage | 82.02 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 19.99 | |||||
Beneish M-Score | -1.46 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 47.5 | |||||
3-Year FCF Growth Rate | 37 | |||||
3-Year Book Growth Rate | 25.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 67 | |||||
9-Day RSI | 59.7 | |||||
14-Day RSI | 57.74 | |||||
3-1 Month Momentum % | 24.64 | |||||
6-1 Month Momentum % | 132.43 | |||||
12-1 Month Momentum % | 91.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.79 | |||||
Quick Ratio | 1.65 | |||||
Cash Ratio | 0.74 | |||||
Days Inventory | 93.55 | |||||
Days Sales Outstanding | 34.78 | |||||
Days Payable | 80.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -50.1 | |||||
Shareholder Yield % | -1.06 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 47.58 | |||||
Operating Margin % | 16.87 | |||||
Net Margin % | 19.01 | |||||
EBITDA Margin % | 18.69 | |||||
FCF Margin % | 0.6 | |||||
OCF Margin % | 4.29 | |||||
ROE % | 67.62 | |||||
ROA % | 38.91 | |||||
ROIC % | 75.27 | |||||
3-Year ROIIC % | 72.03 | |||||
ROC (Joel Greenblatt) % | 83.3 | |||||
ROCE % | 53.29 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 26.22 | |||||
PE Ratio without NRI | 26.22 | |||||
Price-to-Owner-Earnings | 46.19 | |||||
PS Ratio | 4.92 | |||||
PB Ratio | 10.66 | |||||
Price-to-Tangible-Book | 10.78 | |||||
Price-to-Free-Cash-Flow | 53.89 | |||||
Price-to-Operating-Cash-Flow | 138.57 | |||||
EV-to-EBIT | 27.22 | |||||
EV-to-EBITDA | 25.04 | |||||
EV-to-Revenue | 4.68 | |||||
EV-to-FCF | 780.36 | |||||
Price-to-GF-Value | 1.41 | |||||
Price-to-Projected-FCF | 48.5 | |||||
Price-to-Median-PS-Value | 1.76 | |||||
Price-to-Graham-Number | 3.59 | |||||
| Price-to-Net-Current-Asset-Value | 16.17 | |||||
Earnings Yield (Greenblatt) % | 3.67 | |||||
FCF Yield % | 0.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BLS Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 47.176 | ||
| EPS (TTM) (A$) | 0.037 | ||
| Beta | 2.5228 | ||
| 3-Year Sharpe Ratio | 0.91 | ||
| 3-Year Sortino Ratio | 1.97 | ||
| Volatility % | 73.47 | ||
| 14-Day RSI | 57.74 | ||
| 14-Day ATR (A$) | 0.075549 | ||
| 20-Day SMA (A$) | 0.942 | ||
| 12-1 Month Momentum % | 91.11 | ||
| 52-Week Range (A$) | 0.33 - 1.1 | ||
| Shares Outstanding (Mil) | 229.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BLS Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BLS Pharmaceuticals Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| 0.1:1 Stock Split | 2026-06-24 | 1.00 (+2.04%) | ||
| 0.05:1 Stock Split | 2012-03-19 | 30.80 (+0.00%) |
Show
Entries
BLS Pharmaceuticals Ltd Frequently Asked Questions
What is BLS Pharmaceuticals Ltd(ASX:BLS)'s stock price today?
The current price of ASX:BLS is A$0.97. The 52 week high of ASX:BLS is A$1.10 and 52 week low is A$0.33.
When is next earnings date of BLS Pharmaceuticals Ltd(ASX:BLS)?
The next earnings date of BLS Pharmaceuticals Ltd(ASX:BLS) is .
Does BLS Pharmaceuticals Ltd(ASX:BLS) pay dividends? If so, how much?
BLS Pharmaceuticals Ltd(ASX:BLS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on BLS Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers